1887

Abstract

The effect of 3′-azido-3′-deoxythymidine (AZT) on infection of peripheral blood mononuclear cells (PBMCs) isolated from normal adult individuals with human T cell leukaemia/lymphoma virus type I (HTLV-I) was evaluated. Different PBMC samples were exposed to HTLV-I by cocultivation with MT-2 (a chronically infected cell line) in the presence of 20 U/ml of human recombinant interleukin 2 (IL-2) and graded concentrations of AZT. Control and drug-treated cultures, of both infected and uninfected PBMCs, were then grown for several weeks and monitored for virological and immunological parameters. The results showed a concentration- dependent anti-proliferative effect of AZT in both infected and non-infected cultures. Production of both proviral DNA and viral RNA was inhibited not only at the higher concentrations of AZT (8 μM and 32 μM) but also at concentrations as low as 0·12 μM. These results were confirmed by PCR and by flow cytometry analysis for the viral core protein p19. Moreover, treatment with AZT resulted in a decreased expression of CD25 in cultures exposed to HTLV-I as well as in non-infected PBMCs. On the other hand, HLA-DR was down-regulated to a greater extent in drug-treated, virus-exposed cultures in comparison with those not infected. No evidence of the antiviral activity of AZT was observed in PBMC cultures already infected by HTLV-I or in MT-2 cells. These findings demonstrate that treatment with AZT, when given at the time of infection with HTLV-I, has a marked protective effect on PBMCs.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-5-1007
1997-05-01
2022-08-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/5/9152417.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-5-1007&mimeType=html&fmt=ahah

References

  1. Chi D. T., Duesberg P. H. 1995; The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. Genetica 95:103–109
    [Google Scholar]
  2. Cooney D. A., Ahluwalia G., Mitsuya H., Friland A., Johnson M., Hao Z., Dalal M., Balzarini J., Broder S., Johns D. G. 1987; Initial studies of the cellular pharmacology of 2′-3′-dideoxyadenosine, an inhibitor of HIV infectivity. Biochemical Pharmacology 36:1765–1768
    [Google Scholar]
  3. Depper J. M., Leonard W. J., Kronke M., Waldmann T. A., Greene W. C. 1984; Augmented T cell growth factor receptor expression in HTLV-I infected human leukemic T cells. Journal of Immunology 133:1691–1695
    [Google Scholar]
  4. Dianzani F., Antonelli G., Turriziani O., Riva E., Simeoni E., Signoretti C., Strosselli S., Cianfriglia M. 1994; Zidovudine induces the expression of cellular resistance affecting its antiviral activity. Aids Research and Human Retroviruses 10:1471–1478
    [Google Scholar]
  5. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedon J. M., Groopman J. E., Mildvan D., Schooley R. T., Jackson G. G., Durack D. T., King D. the AZT collaborative working group 1987; The efficacy of azidothymidine (AZT) in treatments of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317:185–191
    [Google Scholar]
  6. Franchini G. 1995; Molecular mechanisms of human T-cell leukemia/lymphoma virus type I infection. Blood 86:3619–3639
    [Google Scholar]
  7. Gill S. P., Harrington W. J. R., Kaplan M. H., Ribeiro R. C., Bennet J. M., Liebman H. A., Berstein-Singer M., Espina B. M., Cabral L., Allen S., Kornblau S., Pike M. C., Levine A. M. 1995; Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. New England Journal of Medicine 332:1744–1748
    [Google Scholar]
  8. Heagy W., Crumpacker C., Lopez P. A., Finberg R. W. 1991; Inhibition of immune functions by antiviral drugs. Journal of Clinical Investigation 87:1916–1924
    [Google Scholar]
  9. Hermine O., Bouscary D., Gessain A., Turlure P., Leblond V., Franck N., Buzyn-Veil A., Macintyre E., Dreyfus F., Bazarbachi A. 1995; Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. New England Journal of Medicine 332:1749–1751
    [Google Scholar]
  10. Hino S., Yamaguchi K., Katamine S., Sugiyama H., Amagasaki T., Kinoshita K., Yoshida Y., Doi H., Tsuji Y., Miyamoto T. 1985; Mother to child transmission of human T-cell leukemia virus type I. Japanese Journal of Cancer Research 76:474–480
    [Google Scholar]
  11. Hoffman P. M., Dhib-Jalbut S., Mikovitis J. A., Robbins D. S., Wolf A. L., Bergey G. H., Lohrey N. C., Wieslow O. S., Ruscetti F. W. 1992; Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proceedings of the National Academy of Sciences, USA 89:11784–11788
    [Google Scholar]
  12. Hoxie J. A., Matthews D. M., Cines D. B. 1984; Infection of human endothelial cells by human T-cell leukemia virus type I. Proceedings of the National Academy of Sciences, USA 81:7591–7595
    [Google Scholar]
  13. Isono T., Ogawa K., Seto A. 1990; Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leukemia Research 14:841–847
    [Google Scholar]
  14. Jacobson S., Raine C. S., Mingioli E. S., McFarlin D. E. 1988; Isolation of an HTLV-I-like retrovirus from patients with tropical spastic paraparesis. Nature 331:540–543
    [Google Scholar]
  15. Kimata J. T., Ratner L. 1991; Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type-I mediated lymphocyte immortalization. Journal of Virology 65:4398–4407
    [Google Scholar]
  16. Lacal P. M., Puglianiello A., Bonmassar E., D’Onofrio C. 1995; Effects of cyclopentanone prostaglandins on myeloid cells during early infection with HTLV-I. I. Cell differentiation determines sensitivity to prostaglandins and virus infection. Journal of Pharmacology and Experimental Therapeutics 271:1086–1095
    [Google Scholar]
  17. Macchi B., Popovic M., Allavena P., Ortaldo J., Rossi P., Gallo R. C., Bonmassar E. 1987; In vitro susceptibility of different human T-cell subpopulations and resistance of large granular lymphocytes to HTLV-I infection. International Journal of Cancer 40:1–6
    [Google Scholar]
  18. Macchi B., D’Onofrio C., Labianca R. A., Bonmassar E. 1990; Mononuclear cells from peripheral blood of adult donors and from neonatal cord blood are equally protected by alfa and beta interferon against infection with HTLV-I. Pharmacological Research 22:503–514
    [Google Scholar]
  19. Macchi B., D’Atri S., Gentili G., Bonmassar E. 1991; Determination of intracellular p19 core protein in HTLV-I infected cells by flow microcytometry analysis. Journal of Chemotherapy 3:416–419
    [Google Scholar]
  20. Macchi B., Caronti B., Cocchia D., Gremo F., Torelli S., Sogos V., Bonmassar E., Lauro G. M. 1992; Correlation between p19 presence and MHC class II expression in human fetal astroglial cells cocultured with HTLV-I-donor cells. International Journal of Developmental Neuroscience 10:764–767
    [Google Scholar]
  21. Macchi B., Faraoni I., Mastino A., D’Onofrio C., Romeo G., Bonmassar E. 1993; Protective effect of interferon Beta on human T cell leukemia virus type I infection of CD4+ T cells isolated from human cord blood. Cancer Immunology Immunotherapy 37:97–104
    [Google Scholar]
  22. Matsushita S., Mitsuya H., Reitz M. S., Broder S. 1987; Pharmacological inhibition of in vitro infectivity of human T-lymphotropic virus type I. Journal of Clinical Investigation 80:394–400
    [Google Scholar]
  23. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehram S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 1985; 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and the cytopathic effect of human T-lymphotropic virus type III/lymphoadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences, USA 82:7906–8100
    [Google Scholar]
  24. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Outsuki Y., Shirashy Y., Nagata K., Hinuma Y. 1981; Detection of type C retrovirus particles on a cord blood T-cell line derived by cocultivation of normal human lymphocytes and human leukemic T-cells. Nature 296:770–772
    [Google Scholar]
  25. Nishioka K., Maruyama I., Sato K., Kitajiama Y., Nakajiama Y., Osame M. 1989; Chronic inflammatory arthropathy associated with HTLV-I. Lancet i:441
    [Google Scholar]
  26. Okochi K., Sato H., Hinuma Y. 1984; A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sanguinis 46:245–253
    [Google Scholar]
  27. Osame M., Izumo S., Igata A., Matsumoto M., Matsumoto T., Sonoda S., Tara M., Shibata Y. 1986; Blood transfusion and HTLV-1 associated myelopathy. Lancet ii:104–105
    [Google Scholar]
  28. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A. 1986b; HTLV-I associated myelopathy, a new clinical entity. Lancet i:1031–1032
    [Google Scholar]
  29. Pesce C., Ciprani F., D’Onofrio C., Alvino E., Perno C. F., Bonmassar E., Caliò R. 1987; Low concentration of suramin can reduce in vitro infection of human cord blood lymphocytes with HTLV- I during long-term culture. Antiviral Research 8:247–260
    [Google Scholar]
  30. Poiesez B. J., Ruscetti F. W., Gadzar A. F., Bunn P. A., Minna J. D., Gallo R. C. 1980; Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proceedings of the National Academy of Sciences, USA 77:7415–7419
    [Google Scholar]
  31. Poli G., Orenstein J. M., Kinter A., Folks T. M., Fauci A. 1989; Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575–577
    [Google Scholar]
  32. Sagawa K., Mochizuki M., Masuoka K., Katagiri K., Katayama T., Maeda T., Tanimoto A., Sugita S., Watanabe T., Itoh K. 1995; Immunopathological mechanism of human T cell lymphotropic virus type I (HTLV-I) uveitis. Detection of HTLV-I infected cells in the eye and their constitutive cytokine production. Journal of Clinical Investigation 95:852–858
    [Google Scholar]
  33. Sambrook J., Fritsch E. F., Maniatis T. 1989 Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  34. Silvestri I., Albonici L., Ciotti M., Lombardi M. P., Sinibaldi P., Manzari V., Orlando P., Carretta F., Strazzullo G., Grippo P. 1995; Antimitotic and antiviral activities of Kelletinin A in HTLV-I infected MT-2 cells. Experientia 51:1076–1780
    [Google Scholar]
  35. Sodroski J. 1992; The human T-cell leukemia virus (HTLV) transactivator (TAX) protein. Biochimica et Biophysica Acta 1114:19–29
    [Google Scholar]
  36. Styrt B. A., Piazza-Hepp T. D., Chikami G. K. 1996; Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Research 31:121–135
    [Google Scholar]
  37. Tochikura T. S., Nakashima H., Yamamoto N. 1989; Antiviral agents with activity against human retroviruses. Journal of Acquired Immune Deficiency Syndromes 2:441–447
    [Google Scholar]
  38. Viora M., Camponeschi B. 1995; Down-regulation of interleukin-2 receptor gene activation and protein expression by dideoxynucleoside analogs. Cellular Immunology 163:289–295
    [Google Scholar]
  39. Yoshida M., Miyoshi I., Hinuma Y. 1982; Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proceedings of the National Academy of Sciences, USA 79:2031–2035
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-5-1007
Loading
/content/journal/jgv/10.1099/0022-1317-78-5-1007
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error